Advent International Partners with BioDuro to Expand Footprint in Global CDMO Market
VCBeat (WeChat Official Account: vcbeat) has learned that on January 28, private equity firm Advent International announced a partnership with BioDuro, a global leading contract research and development organization (CRDO) in the life sciences sector, aimed at supporting the rapid growth of BioDuro, a major provider of integrated drug discovery, development, and manufacturing services.
BioDuro, with operations in San Diego, California, as well as Beijing and Shanghai, China, is the preferred partner for drug discovery and development projects. BioDuro is committed to delivering high-quality, integrated discovery services, including medicinal chemistry, drug metabolism and pharmacokinetics (DMPK), biologics and biological services, and translational oncology services such as “live tumor banks” derived from molecular responses. BioDuro will expand its scale of development by establishing new research bases in China and enhancing its current cGMP pharmaceutical manufacturing and new preclinical discovery facilities in San Diego.
Dr. Masood Tayebi, Chairman and Founder of BioDuro, stated, “Through our partnership with Advent International, BioDuro can accelerate its growth and better serve our clients. We recognize the significant potential of our offerings and can leverage cross-selling opportunities to ensure we meet customer needs at every stage of drug discovery and development.”
“Advent International has been closely monitoring the healthcare sectors in the United States and China in recent years. We believe that partnering with BioDuro presents an excellent opportunity to drive growth in the global CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) markets. As global pharmaceutical and biotechnology companies continue to prioritize drug discovery, BioDuro will expand its market share leveraging its strong customer reputation,” commented Filippo de Vecchi, Managing Director and Co-Head of Greater China at Advent International. “Drawing on Advent International’s extensive investment experience in the global healthcare industry, we look forward to working closely with BioDuro and its existing management team to expand the company’s global footprint.”
Advent International has extensive investment experience in the healthcare industry. Over the past 28 years, the firm has invested a total of $6.7 billion in 41 companies across 14 countries worldwide. In addition to BioDuro, its recent investments in the pharmaceutical and CRO sectors include Zentiva, Grupo Farmacéutico Somar, and Syneos Health.
BioDuro is a global leader in contract research and development organization (CRDO) for the life sciences, providing comprehensive drug discovery services to biopharmaceutical clients and partners. These services span from target identification to Investigational New Drug (IND) applications, as well as Good Manufacturing Practice (GMP) manufacturing of drugs for clinical trials. Leveraging its unique technology platforms, BioDuro helps biopharmaceutical partners accelerate program development and mitigate risks, thereby delivering higher-value outcomes.
Advent International, founded in 1984, is one of the largest and most experienced private equity investors globally. With offices across four continents, Advent International has built a globally integrated team of more than 190 investment professionals in North America, Europe, Latin America, and Asia. The firm focuses on investments in five core sectors: business financial services, healthcare, industrials, retail and consumer, and technology, media, and telecommunications.
(Compiled by Liao Min)